Breitenecker G, Neunteufel W, Bieglmayer C, Kölbl H, Schieder K
Second Department of Obstetrics and Gynecology, University of Vienna, Austria.
Int J Gynecol Pathol. 1989;8(2):97-102. doi: 10.1097/00004347-198906000-00002.
Tumor markers CA 125, CA 19-9, and carcinoembryonic antigen (CEA) were detected by immunohistochemistry in paraffin embedded tissue samples obtained from two different locations in 35 ovarian tumors. In addition, serum concentrations of these tumor markers were measured before cytoreductive surgery. The staining reaction was heterogeneous in different parts of the tumor as well as within the parenchyma. Of the marker positive tumors, a staining reaction was observed in both tissue samples in only 10 of 22 cases for CA 125, in eight of 13 cases for CEA, and in three of eight cases for CA 19-9. Eighty-one percent of the patients whose tumor was positive for CA 125 also showed elevated serum levels of this marker. A poor correlation was found between tissue and circulating CA 19-9 levels. CEA was detected in 28% of the tumors and seemed to be valuable only for monitoring in rare cases of ovarian cancer. For purposes of selecting a marker for monitoring of patients with ovarian carcinoma, immunohistochemistry has a predictive value for CA 125 only. In order to better define the marker expressed in a tumor, it is necessary to examine at least two samples of different parts of the malignant tissue.
通过免疫组织化学方法，在取自35例卵巢肿瘤两个不同部位的石蜡包埋组织样本中检测肿瘤标志物CA 125、CA 19 - 9和癌胚抗原（CEA）。此外，在肿瘤细胞减灭术前测量这些肿瘤标志物的血清浓度。肿瘤不同部位以及实质内的染色反应均呈异质性。在标志物阳性的肿瘤中，CA 125的22例中仅10例、CEA的13例中仅8例、CA 19 - 9的8例中仅3例在两个组织样本中均观察到染色反应。肿瘤CA 125呈阳性的患者中，81%血清中该标志物水平也升高。发现组织和循环中的CA 19 - 9水平之间相关性较差。28%的肿瘤中检测到CEA，似乎仅在罕见的卵巢癌病例监测中具有价值。为了选择用于监测卵巢癌患者的标志物，免疫组织化学仅对CA 125具有预测价值。为了更好地确定肿瘤中表达的标志物，有必要检查恶性组织不同部位的至少两个样本。
